6/9/2010

Salix Pharmaceuticals submitted an application to the FDA to promote Xifaxan as a treatment for irritable bowel syndrome. The drug is already approved for traveler's diarrhea and hepatic encephalopathy stemming from advanced liver disease.

Related Summaries